D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)

Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and a...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Maher, T M, Bareille, P, Costa, M J, Fahy, W A, Harrison, S A, Holman, B F, Lukey, P, Man, Y, Saunders, P, Simpson, J K, Toshner, R, Woodcock, H V, Yang, S, Marshall, R P
Format: Article
Language:English
Subjects:
Pulmonary fibrosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title American journal of respiratory and critical care medicine
container_volume 195
creator Maher, T M
Bareille, P
Costa, M J
Fahy, W A
Harrison, S A
Holman, B F
Lukey, P
Man, Y
Saunders, P
Simpson, J K
Toshner, R
Woodcock, H V
Yang, S
Marshall, R P
description Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and again during the course of the dosing period.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926862004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926862004</sourcerecordid><originalsourceid>FETCH-proquest_journals_19268620043</originalsourceid><addsrcrecordid>eNqNis1Og0AUhYnRxPrzDjdx0yaSzMBAobtairJQCBrrrhlgaqcOM8gdFn0yX0-MPoCrc853vhNnQgM_cFk8J6djJ3PfZSx-O3cuEA-EUC-iZOJ8JZRBVqQLeMxfs6d7SPNysyyTBSyh5LoxrUTR3EKheC0q466Mtr1R6oclZqiUcO-U1OMqRSe4HSEKWGPNFbfSaHi2Q3OEjbR7yFvZcSVRVjB9xw-PeiELohlkGopRFtrir5g10nTc7mUNxaBao3l_hFRWvUGJMJXdbnblnO24QnH9l5fOTbp-WT24XW8-B4F2ezBDr8drS2MvjEKPEOb_z_oG1U5ggA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926862004</pqid></control><display><type>article</type><title>D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><source>EZB Electronic Journals Library</source><creator>Maher, T M ; Bareille, P ; Costa, M J ; Fahy, W A ; Harrison, S A ; Holman, B F ; Lukey, P ; Man, Y ; Saunders, P ; Simpson, J K ; Toshner, R ; Woodcock, H V ; Yang, S ; Marshall, R P</creator><creatorcontrib>Maher, T M ; Bareille, P ; Costa, M J ; Fahy, W A ; Harrison, S A ; Holman, B F ; Lukey, P ; Man, Y ; Saunders, P ; Simpson, J K ; Toshner, R ; Woodcock, H V ; Yang, S ; Marshall, R P</creatorcontrib><description>Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and again during the course of the dosing period.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Pulmonary fibrosis</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Maher, T M</creatorcontrib><creatorcontrib>Bareille, P</creatorcontrib><creatorcontrib>Costa, M J</creatorcontrib><creatorcontrib>Fahy, W A</creatorcontrib><creatorcontrib>Harrison, S A</creatorcontrib><creatorcontrib>Holman, B F</creatorcontrib><creatorcontrib>Lukey, P</creatorcontrib><creatorcontrib>Man, Y</creatorcontrib><creatorcontrib>Saunders, P</creatorcontrib><creatorcontrib>Simpson, J K</creatorcontrib><creatorcontrib>Toshner, R</creatorcontrib><creatorcontrib>Woodcock, H V</creatorcontrib><creatorcontrib>Yang, S</creatorcontrib><creatorcontrib>Marshall, R P</creatorcontrib><title>D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)</title><title>American journal of respiratory and critical care medicine</title><description>Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and again during the course of the dosing period.</description><subject>Pulmonary fibrosis</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNis1Og0AUhYnRxPrzDjdx0yaSzMBAobtairJQCBrrrhlgaqcOM8gdFn0yX0-MPoCrc853vhNnQgM_cFk8J6djJ3PfZSx-O3cuEA-EUC-iZOJ8JZRBVqQLeMxfs6d7SPNysyyTBSyh5LoxrUTR3EKheC0q466Mtr1R6oclZqiUcO-U1OMqRSe4HSEKWGPNFbfSaHi2Q3OEjbR7yFvZcSVRVjB9xw-PeiELohlkGopRFtrir5g10nTc7mUNxaBao3l_hFRWvUGJMJXdbnblnO24QnH9l5fOTbp-WT24XW8-B4F2ezBDr8drS2MvjEKPEOb_z_oG1U5ggA</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Maher, T M</creator><creator>Bareille, P</creator><creator>Costa, M J</creator><creator>Fahy, W A</creator><creator>Harrison, S A</creator><creator>Holman, B F</creator><creator>Lukey, P</creator><creator>Man, Y</creator><creator>Saunders, P</creator><creator>Simpson, J K</creator><creator>Toshner, R</creator><creator>Woodcock, H V</creator><creator>Yang, S</creator><creator>Marshall, R P</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)</title><author>Maher, T M ; Bareille, P ; Costa, M J ; Fahy, W A ; Harrison, S A ; Holman, B F ; Lukey, P ; Man, Y ; Saunders, P ; Simpson, J K ; Toshner, R ; Woodcock, H V ; Yang, S ; Marshall, R P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19268620043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Pulmonary fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maher, T M</creatorcontrib><creatorcontrib>Bareille, P</creatorcontrib><creatorcontrib>Costa, M J</creatorcontrib><creatorcontrib>Fahy, W A</creatorcontrib><creatorcontrib>Harrison, S A</creatorcontrib><creatorcontrib>Holman, B F</creatorcontrib><creatorcontrib>Lukey, P</creatorcontrib><creatorcontrib>Man, Y</creatorcontrib><creatorcontrib>Saunders, P</creatorcontrib><creatorcontrib>Simpson, J K</creatorcontrib><creatorcontrib>Toshner, R</creatorcontrib><creatorcontrib>Woodcock, H V</creatorcontrib><creatorcontrib>Yang, S</creatorcontrib><creatorcontrib>Marshall, R P</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maher, T M</au><au>Bareille, P</au><au>Costa, M J</au><au>Fahy, W A</au><au>Harrison, S A</au><au>Holman, B F</au><au>Lukey, P</au><au>Man, Y</au><au>Saunders, P</au><au>Simpson, J K</au><au>Toshner, R</au><au>Woodcock, H V</au><au>Yang, S</au><au>Marshall, R P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Omipalisib is an ATP-competitive reversible PI3K/mTOR inhibitor, which exhibits potent inhibition of all three classes of PI3 kinases and FRAP1. A BAL and [18F]-FDG-PET/CT scan was conducted twice during the study to evaluate additional PD markers; once, at least 2 days before dosing commenced and again during the course of the dosing period.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_journals_1926862004
source Freely Accessible Science Journals - check A-Z of ejournals; EZB Electronic Journals Library
subjects Pulmonary fibrosis
title D14 IPF: MOVING FORWARD: A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study With Omipalisib (gsk2126458) In Patients With Idiopathic Pulmonary Fibrosis (ipf)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A49%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=D14%20IPF:%20MOVING%20FORWARD:%20A%20Randomised,%20Placebo-Controlled,%20Double-Blind,%20Repeat%20Dose%20Escalation%20Study%20With%20Omipalisib%20(gsk2126458)%20In%20Patients%20With%20Idiopathic%20Pulmonary%20Fibrosis%20(ipf)&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Maher,%20T%20M&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926862004%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_19268620043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1926862004&rft_id=info:pmid/&rfr_iscdi=true